Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 31;20(1):e0318463.
doi: 10.1371/journal.pone.0318463. eCollection 2025.

Anticoagulants utilization in eight hospitals within the Luzhou region from 2019 to 2023

Wei Luo  1   2 , Yan Li  3 , Jiali Yang  1   2 , Yang Liu  1   2 , Yue Shi  1   2 , Hongli Luo  1
Affiliations

Anticoagulants utilization in eight hospitals within the Luzhou region from 2019 to 2023

Wei Luo et al. PLoS One. .

Abstract

Background: With the increasing utilization of anticoagulants, the selection of appropriate anticoagulants has emerged as a significant quandary. The objective of this study was to evaluate recent trend in the utilization and expenditure of anticoagulants within a specific region, aiming to provide valuable insights into the optimal choice of anticoagulants across other healthcare facilities.

Methods: The utilization of anticoagulants was retrospectively analyzed. The data on anticoagulant utilizations in tertiary-care hospitals within a district were collected from January 2019 to December 2023. The expenditure, defined daily doses (DDDs), and defined daily cost (DDC) were calculated. The trends in the utilization and expenditure of anticoagulants were examined using linear regression analysis.

Results: From 2019 to 2023, the DDDs of rivaroxaban demonstrated a significant annual increase in most hospitals (p < 0.05). Only a few hospitals exhibited a gradual rise in the consumption of low molecular weight heparin (LMWH) over the same period (p < 0.05). The trend of heparin sodium and warfarin varied across different hospitals. The implementation of the centralized procurement policy, however, resulted in a decline in the consumption of rivaroxaban and LMWH in 2021 and 2022 respectively. The DDC value of rivaroxaban experienced a substantial decrease over the past five years (p = 0.020), declining from 55.20 Chinese Yuan (CNY) in 2019 to 4.28 CNY in 2023. Conversely, there was a slight increase noted in the DDC of heparin sodium during this time frame (p = 0.042).

Conclusion: Over the past five years (2019-2023), there has been an increase in the utilization of rivaroxaban and LMWH. However, their expenditure has decreased. In addition, the utilization and expenditure of warfarin and heparin sodium remained relatively stable. The application prospects of rivaroxaban and LMWH are promising.

PubMed Disclaimer

Conflict of interest statement

The authors declare there are no conflicts of interest.

Figures

Fig 1
Fig 1. Utilization of anticoagulants at eight hospitals from 2019 to 2023.
DDDs: defined daily doses; LMWH: low molecular weight heparin.
Fig 2
Fig 2. Utilization of anticoagulants from 2019 to 2023.
A: warfarin. B: rivaroxaban; C: heparin sodium; D: LMWH. DDDs: defined daily doses; LMWH: low molecular weight heparin.
Fig 3
Fig 3. The expenditure on anticoagulants in the period of 2019-2023(million CNY).
A: Warfarin; B: Rivaroxaban; C: Heparin sodium; D: LMWH. LMWH: low molecular weight heparin.
Fig 4
Fig 4. Outpatient utilization of anticoagulants from 2019 to 2023.
A: Warfarin; B: Rivaroxaban; C: Heparin sodium; D: LMWH. DDDs: defined daily doses; LMWH: low molecular weight heparin.
Fig 5
Fig 5. Inpatient utilization of anticoagulants from 2019 to 2023.
A: Warfarin; B: rivaroxaban; C: Heparin sodium; D: LMWH. DDDs: defined daily doses; LMWH: low molecular weight heparin.
Fig 6
Fig 6. DDC for four anticoagulants from 2019 to 2023.
DDC: defined daily cost.
See this image and copyright information in PMC

References

    1. Voukalis C, Lip GYH, Shantsila E. Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease. Expert Opin Pharmacother. 2016;17: 2033–2047. doi: 10.1080/14656566.2016.1232393 - DOI - PubMed
    1. Arnold MJ. Thromboembolic Disease. Prim Care: Clin Off Pract. 2024;51: 65–82. doi: 10.1016/j.pop.2023.07.004 - DOI - PubMed
    1. Lutsey PL, Zakai NA. Epidemiology and prevention of venous thromboembolism. Nat Rev Cardiol. 2023;20: 248–262. doi: 10.1038/s41569-022-00787-6 - DOI - PMC - PubMed
    1. National Health Commission of the People’s Republic of China [Internet]. National healthcare quality and safety improvement targets in 2021. 2021 Feb 20 [cited 2024 Nov 19]. http://www.nhc.gov.cn/yzygj/s7657/202102/8c53313663284a7ba146648509538ee...
    1. National Health Commission of the People’s Republic of China [Internet]. National healthcare quality and safety improvement targets in 2022. 2022 Mar 2 [cited 2024 Nov 21]. http://www.nhc.gov.cn/yzygj/s3585/202203/ffed3474b1884058841a07c144ad094...

MeSH terms